The Efficacy and Safety of Reconyl in Acute Cough Treatment

There will be 2 groups of treatment; each group will consist of 72 subjects with the treatment regimens for 7 days:

Treatment I : 1 tablet of Reconyl 225 mg three times daily; Treatment II : 1 tablet of Reconyl Placebo three times daily.

Subjects will be asked to come to the clinic at Baseline and at Visit 1 (Day 7) for evaluation of treatment efficacy. During the 7-day study period, subjects should record product consumption, any adverse events, and their daily VAS score in the provided Patient's Diary.

The safety profile of study medication other than vital signs and adverse event will be measured at Baseline and End of Study.

Inclusion criteria

• Signed informed consent from the subject or the subject's legally acceptable representatives (must obtained before any trial related activities)
• Male or female subjects, aged 18-50 years at screening
• Experience acute cough, defined as sudden onset dominant or main symptom of acute or worsened cough, with or without sputum, in the span of 72 hours, avoiding prescription and non-prescription cough-relieving medications (e.g. antitusives such as codeine-based cough supressants or dextromethorphan HBr, and mucolytics such as N-acetylsistein, Bromhexin and Ambroxol), within 24 hours before entering the study.
• The condition of the patient does not have any illness other than acute cough that could possibly interfere with the study evaluation, such as chronic obstructive pulmonary disease (COPD), suspect GERD, rhinitis, asthma, tuberculosis (TB), and pneumonia.
• Cooperative and able to fill out study material

Exclusion criteria

• Subject with febrile within 24 hours before screening, or has body temperature ≥ 38°C during screening visit
• Personal/family history of allergy or hypersensitivity or contradiction to any component of the drugs
• History or clinical evidence of immunosuppression according to investigator assessment, or currently under treatment with immunosuppressive agents
• Participation in any other trial less than 90 days before
• Pregnancy or lactation
• History of drug or alcohol abuse within 12 months prior to screening